The European Medicines Agency (EMA) aims to decide in early October whether to endorse a third dose of the Pfizer-BioNTech COVID-19 vaccine to be given half a year after the initial two-shot course, saying breakthrough infections added some urgency to its review. "The outcome of this evaluation is expected in early October, unless supplementary information is needed," EMA's head of vaccines strategy, Marco Cavaleri, told a press briefing on Thursday.
CureVac said it is canceling deals with two companies it had contracted to manufacture its experimental Covid-19 vaccine.
German biotech firm CureVac said on Tuesday it cancelled contract manufacturing deals for its experimental COVID-19 vaccine with two prospective partners, after rivals with approved shots have boosted production. Agreements with Celonic Group of Switzerland and Germany's Wacker would be terminated but existing production deals with Rentschler Biopharma and Novartis would remain unchanged, CureVac said in a statement. CureVac fell far behind rivals BioNTech, a partner of Pfizer, and Moderna, in trying to develop an mRNA-based COVID-19 vaccine.